Increased plasma asymmetric dimethylarginine (ADMA) levels in retinal venous occlusive disease

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 3, 2008, Pages 387-392

  Zinellu, Angelo ^a,b   Pinna, Antonio ^a   Sotgia, Salvatore ^a,b   Zinellu, Elisabetta ^a   Usai, Maria Franca ^a   Carta, Francesco ^a   Gaspa, Leonardo ^a,b   Deiana, Luca ^a   Carru, Ciriaco ^a,b  

^a UNIVERSITY OF SASSARI   (Italy)

^b NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

Asymmetric dimethylarginine (ADMA); Dimethylarginine dimethylaminohydrolase (DDAH) inhibition; Retinal vein occlusion; Symmetric dimethylarginine (SDMA)

Indexed keywords

CYSTEINE; DIMETHYLARGININASE; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE;

AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CAPILLARY ELECTROPHORESIS; COHORT ANALYSIS; CONTROL GROUP; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA VEIN OCCLUSION; STATISTICAL SIGNIFICANCE;

AGED; ARGININE; CASE-CONTROL STUDIES; COHORT STUDIES; CYSTEINE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RISK FACTORS;

EID: 39849108241     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.063     Document Type: Article

References (41)

1. Cooke JP, Tsao PS. Is NO an endogenous antiatherogenic molecule? Arterioscler Thromb 1994;14:653-5.
2. McDermott JR. Studies on the catabolism of NG-methylarginine, NG,NG-dimethylarginine and NG,N′G-dimethylarginine in the rabbit. Biochem J 1976;154:179-84.
3. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, et al. LDL cholesterol upregulates synthesis of asymmetric dimethylarginine (ADMA) in human endothelial cells. Involvement of S-adenosylmethionine dependent methyltransferases. Circ Res 2000;87:99-105.
4. Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20:1557-64.
5. Böger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med 2003; 41:1467-72.
6. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
7. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of symmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-7.
8. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001;358:2127-8.
9. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995;36:182-91.
10. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study. Arch Ophthalmol 1996;114:1243-7.
11. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98:133-41.
12. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006;124:726-32.
13. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999;33:652-8.
14. Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Boger RH. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 2005;35:622-6.
15. Zinellu A, Sotgia S, Zinellu E, Pinna A, Carta F, Gaspa L, et al. High throughput CZE-UV assay for arginine and dimethylated arginines determination in human plasma. Electrophoresis 2007;28:1942-8.
16. Zinellu A, Carru C, Galistu F, Usai MF, Pes GM, Baggio G, et al. N-methyl-D-glucamine improves the capillary electrophoresis performance in the total plasma thiols measurement. Electrophoresis 2003;24:2796-804.
17. Zinellu A, Carru C, Usai MF, Sotgia S, Deiana L. Determination of creatinine in human serum by short-end injection capillary zone electrophoresis. Electrophoresis 2004;25:1096-101.
18. Whitworth JA. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-92.
19. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104:2569-75.
20. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003;23: 1455-9.
21. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109:172-7.
22. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994;14: 753-9.
23. Naruse K, Shimizu K, Muramatsu M, Toki Y, Miyazaki Y, Okumura K, et al. Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. PGH2 does not contribute to impaired endothelium-dependent relaxation. Arterioscler Thromb 1994;14:746-52.
24. Fleck C, Janz A, Schweitzer F, Karge E, Schwertfeger M, Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl 2001;78:S14-8.
25. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996; 114:545-54.
26. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001;131:61-77.
27. The Eye Disease Case-Control Study Group. Risk factors for branch vein occlusion. Am J Ophthalmol 1993;116: 286-96.
28. Williamson TH, Rumley A, Lowe GD. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol 1996;80:203-8.
29. Pinna A, Carru C, Zinellu A, Dore S, Deiana L, Carta F. Plasma homocysteine and cysteine levels in retinal venous occlusive disease. Invest Ophthalmol Vis Sci 2006;47:4067-71.
30. Jacob N, Bruckert E, Giral P, Foglietti MJ, Turpin G. Cysteine is a cardiovascular risk factor in hyperlipidemic patients. Atherosclerosis 1999;146:53-9.
31. El-Khairy L, Ueland PM, Refsum H, Graham IM, Vollset SE. Plasma total cysteine as a risk factor for vascular disease. Circulation 2001;103:2544-9.
32. Carru C, Zinellu A, Sotgia S, Chessa R, Piredda F, Casu MA, et al. Carotid narrowing degree and plasma thiol levels in carotid endarterectomy patients. Clin Chem Lab Med 2005;43:1015-9.
33. Ozkan Y, Ozkan E, Simsek B. Plasma total homocysteine and cysteine levels as cardiovascular risk factors in coronary heart disease. Int J Cardiol 2002;82:269-77.
34. Stamler JS, Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev 1996;54:1-30.
35. Nishiuch Y, Sasaki M, Nakayasu M, Oikawa A. Cytotoxicity of cysteine in culture media. In Vitro 1976;12:635-8.
36. Dudman NP, Hicks C, Wang J, Wilcken DE. Human arterial endothelial cell detachment in vitro: its promotion by homocysteine and cysteine. Atherosclerosis 1991;91: 77-83.
37. Saez G, Thornalley PJ, Hill HA, Hems R, Bannister JV. The production of free radicals during the autoxidation of cysteine and their effect on isolated rat hepatocytes. Biochim Biophys Acta 1982;719:24-31.
38. Lakshminarayanan V, Lewallen M, Frangogiannis NG, Evans AJ, Wedin KE, Michael LH, et al. Reactive oxygen intermediates induce monocyte chemotactic protein-1 in vascular endothelium after brief ischemia. Am J Pathol 2001;159:1301-11.
39. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987;262:10098-103.
40. Di Crecchio L, Battaglia Parodi M, Sanguinetti G, Iacono P, Ravalico G. Hyperhomocysteinemia, and the methylenetetrahydrofolate reductase C677T mutation in patients under 50 years of age affected by central retinal vein occlusion. Ophthalmology 2004;111:940-5.
41. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;54:1-30.